Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04103333 · ClinicalTrials.gov registry record · Early Phase 1
Angelman Syndrome (AS) Biomarker Study
A Early Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT04103333 is a Early Phase 1 study that has completed, run by Biogen. The registered enrollment target is 20 participants.
The verdict
NCT04103333, a Early Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective of this study is to measure ubiquitin-protein ligase E3A (UBE3A) protein levels in cerebrospinal fluid (CSF) and to evaluate its utility as a biomarker in support of the development of therapies for AS.
Interventions
- PROCEDURE Lumbar Puncture
- PROCEDURE Blood Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-12-18 |
| Est. Completion | 2022-01-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04103333
The ClinicalTrials.gov registry entry for NCT04103333 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lumbar Puncture is the first listed.
NCT04103333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04103333 about?
NCT04103333 is a clinical study titled "Angelman Syndrome (AS) Biomarker Study". The primary objective of this study is to measure ubiquitin-protein ligase E3A (UBE3A) protein levels in cerebrospinal fluid (CSF) and to evaluate its utility as a biomarker in support of the development of therapies for AS.
What is the current status of trial NCT04103333?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2019-12-18. Estimated completion is 2022-01-02.
What interventions are being tested in trial NCT04103333?
The interventions under investigation include: Lumbar Puncture (PROCEDURE), Blood Collection (PROCEDURE).
Who is sponsoring clinical trial NCT04103333?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.